Streetbeat News

Regulatory

NAMS

NewAmsterdam Pharma (NASDAQ:NAMS) has announced the issuance of a new patent for obicetrapib by the USPTO, extending the patent term until July 2043. This development is significant for the company's portfolio of non-statin medicines targeting cardiovascular disease.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:21 pm

META

Meta Platforms Inc. (NASDAQ:META) has updated its data use policies to include publicly shared content from European users on Instagram and Facebook for AI model training. This move has sparked multiple complaints from the digital rights group Noyb, which argues that these practices violate EU law. Despite these challenges, Meta's stock has surged 40% year-to-date and is nearing its all-time high.

Portfolio Pulse from Zaheer Anwari

June 11, 2024 | 12:14 pm

POAI

Predictive Oncology has introduced a new technology called 'Membrane Protein Factory' for expressing functional and stable G-Protein Coupled Receptors (GPCRs). The company has filed for intellectual property protection for this technology, which aims to produce purified and biologically active membrane proteins for drug development. The annual US GPCR market was valued at nearly $3.5 billion in 2022 and is expected to grow more than 5% annually through 2030.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:10 pm

SXTP

60 Degrees Pharmaceuticals shares are trading higher after the company announced FDA orphan drug designation for tafenoquine to treat acute babesiosis.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:07 pm

TLSA

Tiziana Life Sciences has received FDA acceptance for its Fast Track Designation submission for intranasal Foralumab, aimed at treating non-active secondary-progressive multiple sclerosis (na-SPMS).

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:06 pm

PCT

PureCycle Technologies has received a Letter of No Objection from the FDA, confirming that its PureFive ultra-pure recycled resin is suitable for use in food-contact applications.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:04 pm

CMND

Clearmind Medicine Inc. (NASDAQ:CMND) has announced advancements in its proprietary MEAI-based alcohol substitute beverage program. The company is moving forward with the last pre-clinical study required for a novel-food application submission.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:00 pm

SXTP

60 Degrees Pharmaceuticals has received FDA Orphan Drug Designation for tafenoquine to treat acute babesiosis. This designation provides incentives like market exclusivity, tax credits, and fee exemptions. The company has also partnered with Tufts Medical Center to conduct a clinical trial for tafenoquine's efficacy and safety in treating human babesiosis.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:00 pm

DIVD

IDVO

TM

Toyota Motor Corp. (NYSE:TM) faces a certification crisis that extends beyond Japan, potentially impacting its operations in the EU. Discrepancies in vehicle certifications conflict with UN standards, leading to halted sales of several models in Japan. The issue affects two production lines and comes ahead of Toyota's annual shareholder meeting. Toyota stock has gained 36% in the last 12 months, and investors can gain exposure via Amplify CWP International Enhanced Dividend Income ETF (NYSE:IDVO) and Altrius Global Dividend ETF (NASDAQ:DIVD).

Portfolio Pulse from Shivani Kumaresan

June 11, 2024 | 11:59 am

BIIB

LLY

Eli Lilly's (LLY) shares are trading higher premarket after an FDA advisory committee gave a favorable verdict on its Alzheimer's treatment, donanemab. The panel's endorsement moves the treatment closer to final FDA approval. The news contrasts Lilly's approach with Biogen's (BIIB) Alzheimer's drug, Leqembi.

Portfolio Pulse from Shivani Kumaresan

June 11, 2024 | 11:51 am